DrugPatentWatch Database Preview
Hikma Intl Pharms Company Profile
What is the competitive landscape for HIKMA INTL PHARMS, and when can generic versions of HIKMA INTL PHARMS drugs launch?
HIKMA INTL PHARMS has forty-three approved drugs.
There are five US patents protecting HIKMA INTL PHARMS drugs.
Summary for Hikma Intl Pharms
| US Patents: | 5 |
| Tradenames: | 30 |
| Ingredients: | 30 |
| NDAs: | 43 |
Drugs and US Patents for Hikma Intl Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma Intl Pharms | BUTALBITAL, ASPIRIN AND CAFFEINE | aspirin; butalbital; caffeine | TABLET;ORAL | 086162-002 | Feb 16, 1984 | AA | RX | No | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Hikma Intl Pharms | LISINOPRIL AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 076265-003 | Jul 8, 2002 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Hikma Intl Pharms | RESERPINE | reserpine | TABLET;ORAL | 080975-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for HIKMA INTL PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 0.6 mg | ➤ Subscribe | 2016-06-10 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
